Do some diabetes drugs help your heart?
Assessment of Cardiovascular Risk With Glucagon-Like Peptide 1 Receptor Agonists in Patients With Type 2 Diabetes Using an Alternative Measure to the Hazard Ratio
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some diabetes drugs called GLP-1 agonists might help your heart live longer, but not all of them do.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 533 / 100
Evidence Score
The highest quality evidence. These studies systematically search, appraise, and synthesize results from multiple individual studies, providing the most reliable summary of current knowledge.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
Some diabetes drugs called GLP-1 agonists might help your heart live longer, but not all of them do.
No biological mechanisms were identified in this study. This may be an epidemiological, observational, or survey-based study that reports associations rather than proposing causal biological pathways.
Systematic Reviews & Meta-Analyses
Max 100Randomized Controlled Trials
Max 90Cohort Studies
Max 72Case-Control Studies
Max 58Cross-Sectional Studies
Max 44Case Reports & Case Series
Max 30Expert Opinion & Narrative Reviews
Max 533 / 100
Evidence Score
The highest quality evidence. These studies systematically search, appraise, and synthesize results from multiple individual studies, providing the most reliable summary of current knowledge.
Publication
Related Content
Claims (6)
Liraglutide and exenatide, drugs that activate GLP-1 receptors, lower the frequency of heart attacks, strokes, and hospitalizations for heart failure by acting directly on the heart and metabolism, regardless of whether they cause weight loss.
In adults with type 2 diabetes, the drugs lixisenatide and exenatide do not lower the rate of serious heart problems more than a placebo, based on combined results from multiple clinical trials.
In clinical trials of GLP-1 receptor agonists, the restricted mean survival time measures the actual amount of time patients live longer due to treatment, which is easier to understand than hazard ratios that express relative risk changes.
In adults with type 2 diabetes, treatment with liraglutide or semaglutide is linked to a moderate decrease in the occurrence of serious heart problems and a small increase in survival time over 1.5 to 4.5 years compared to no such treatment.
GLP-1 receptor agonists, a group of diabetes medications, do not raise the risk of serious heart problems in adults with type 2 diabetes.